The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) brings together regulatory authorities and representatives from the pharmaceutical industry from across the globe to discuss a range of technical and scientific considerations for medicinal products and to develop ICH guidance. In this manner, ICH provides a harmonized approach to ensure that safe, effective and high-quality medicines are developed, registered, and maintained in a resource efficient manner whilst meeting high standards. As cell and gene therapy products have become ever more prevalent in the therapeutic landscape, the specific considerations applicable to such products are in need of specific recommendations for revisions to existing ICH guidelines and/or new guideline development. The ICH Cell and Gene Therapies Discussion Group (CGT DG) has been formed, and the Remit was endorsed by the ICH Management Committee in May 2023. In this session we will hear about the scope of ICH CGT DG activities and their progress toward targeted deliverables.
Session Speaker:
ICH CGT DG: Progress Toward Delivering a Strategic Roadmap for ATMPs
Kathleen Francissen, Genentech, A Member of the Roche Group
In addition to the now well-known CAR T (chimeric antigen receptor T cells) and HSC (CD34+ hematopoietic stem cells) cell-based gene therapies, there are several other modes of gene modification as well as cell types already approved and on the horizon…
Our ability to treat diseases previously untreatable through the delivery of adeno-associated virus (AAV)-based gene therapies has been a tremendous advancement in pharmaceutical development…